With a market capitalization (market cap) of $36.1B — a measure of how much the company is worth — Kenvue Inc. is the 416th most valuable company in Consumer Defensive as of August 18, 2026. Shares trade at $18.80, up +0.05% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Visit websiteAs of August 18, 2026, Kenvue Inc. (KVUE) is worth $36.1B — this is its market capitalization, the total value of all its outstanding shares.
Kenvue Inc.’s market cap is $36.1B, which ranks it #416 among the most valuable companies in the Consumer Defensive sector tracked on MarketCapLens.
Kenvue Inc. (KVUE) shares trade at $18.80, up 0.05% on the day, as of August 18, 2026.
Kenvue Inc. trades at a price-to-earnings (P/E) ratio of 24.4, based on its latest share price and annual earnings per share.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025